Photo illustration: Axios. Photo: Courtesy of McKinsey
Some AI drug discovery companies are struggling to win over public investors as shifting business models and uncertain clinical outcomes cloud their prospects.
Why it matters: Big Pharma is deepening its AI partnerships, but drug developers still face pressure to prove the technology can deliver successful medicines and sustainable returns, McKinsey senior partner Alex Devereson tells Axios.
